SYNCORDIS-S.A.
14.5.2019 12:02:02 CEST | Business Wire | Press release
Syncordis S.A., a wholly owned subsidiary of Larsen & Toubro Infotech (LTI), today announced a strategic global partnership with Temenos, the banking software company. This partnership will enable Syncordis to seamlessly offer an array of Temenos certified services to banks across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005422/en/
Equipped with an exclusive focus and comprehensive expertise, Syncordis has established itself as a specialist in implementation of Temenos T24 Transact, the next generation platform for core banking and Temenos WealthSuite. Through the global partnership, Syncordis will attain enhanced capabilities to offer a wide range of services across Temenos product portfolio and manage migration, training, testing and upgrade requirements of Temenos clients worldwide.
Guillaume Desjonqueres, CEO, Syncordis said, “We are excited to partner with Temenos, the market leader in cloud-native, cloud-agnostic banking software, and confident that we will be able to deliver outstanding services and experiences to our customers through this strategic alliance.”
Nachiket Deshpande, COO, LTI said, “As the Financial Services industry undergoes transformation, organizations must co-innovate to solve tough problems for their customers. Syncordis and LTI will partner with Temenos to address this demand, deliver innovation and improve business performance for our global clients in the Banking and Wealth Management space.”
Neal McLoughlin, Head of Partners & Operations, Temenos, said, “At Temenos, we understand the power of partnerships and we have built the most dynamic community in the banking industry. We are delighted to expand our partnership with Syncordis to a global strategic alliances and value their commitment. Together, we will leverage the power of our cloud-native, cloud-agnostic banking software to transform the banking industry.”
Syncordis has developed industry-leading accelerators that help with faster and consistent Temenos implementations and capture the fast-growing market opportunities for banking modernization services. This partnership will establish Syncordis as a trusted Temenos partner for end-to-end implementation, platform upgrades and enhancements for performance tuning.
About Syncordis:
Syncordis S.A., a Luxembourg based LTI Company, delivers high-quality end-to-end implementation and system integration projects with an exclusive focus on Temenos banking software. With 12 offices across the globe and 300+ experts, Syncordis enables its international clients to master their digital transformation and succeed in this ever-changing market. Having recently merged with NIELSEN+PARTNER, Syncordis now combines the business and technical expertise and experience of 15+ years in Temenos T24 Transact and SaaS solutions and production support services with 24+ years in Temenos WealthSuite, Temenos Infinity and DataSource. This makes Syncordis one of the wealth management specialists and one-stop partners for Temenos clients worldwide. For more information please visit www.syncordisconsulting.com .
About Temenos:
Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 firms across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic front office and core banking, payments, fund management and wealth management software products enabling banks to deliver consistent, frictionless customer journeys and gain operational excellence. Temenos customers are proven to be more profitable than their peers: over a seven-year period, they enjoyed on average a 31% higher return on assets, a 36% higher return on equity and an 8.6 percentage point lower cost/income ratio than banks running legacy applications. For more information please visit www.temenos.com .
About LTI:
Larsen & Toubro Infotech (NSE: LTI, BSE: 540005) is a global technology consulting and digital solutions Company helping more than 300 clients succeed in a converging world. With operations in 30 countries, we go the extra mile for our clients and accelerate their digital transformation with LTI’s Mosaic platform enabling their mobile, social, analytics, IoT and cloud journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 28,000 LTItes enable our clients to improve the effectiveness of their business and technology operations, and deliver value to their customers, employees and shareholders. Find more at www.Lntinfotech.com or follow us at @LTI_Global.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005422/en/
Contact:
Media Contact for Syncordis: Clara Bechler Marketing & Communication T +49 40 369 835-12 E cbechler@syncordisconsulting.com Media Contacts for Temenos: Jessica Wolfe Temenos Global Public Relations T +1 610 232 2793 E press@temenos.com Alistair Kellie & Andrew Adie Newgate Communications on behalf of Temenos T +44 20 7680 6550 E allnewgatetemenos@newgatecomms.com Media Contacts for LTI: Neelian Homem PR & Media Relations – India T +91 900 434-5540 E neelian.homem@lntinfotech.com Karin Bakis PR & Media Relations – India T +1 978 998-1578 E karin.bakis@lntinfotech.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom